Evidence map›Paper›PMID 29908962›Full record

ArticleCancer letters2018

Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma.

Chaochu Cui, Yan Chang, Xiaoli Zhang, Sangyong Choi, Henry Tran, Kumar V Penmetsa, Srikant Viswanadha, Liwu Fu, Zui Pan

Open access · greenAbstract read
In one paragraph

Article in Cancer letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Store-operated calcium entry-based targets for novel cancer therapeutic development.The Journal of pharmacology and experimental therapeutics · 2025
    Review
  2. CaBiophysics reports · 2024
    Article
  3. Review
  4. Measurement of Intracellular CaMethods in molecular biology (Clifton, N.J.) · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. ORAI1 CaFrontiers in cell and developmental biology · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. Suppression of store-operated CaCell cycle (Georgetown, Tex.) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Chaochu CuiState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China; College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX, USA; Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, Henan, China.
Yan ChangCollege of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX, USA.
Xiaoli ZhangComprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.
Sangyong ChoiCollege of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX, USA.
Henry TranDepartment of Biology, University of Texas at Arlington, Arlington, TX, USA.
Kumar V PenmetsaRhizen Pharmaceuticals SA, La Chaux-de-Fonds, Switzerland.
Srikant ViswanadhaIncozen Therapeutics Private Limited, Hyderabad, India.
Liwu FuState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: fulw@mail.sysu.edu.cn.
Zui PanCollege of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX, USA. Electronic address: zui.pan@uta.edu.
The University of Texas at Arlington · USSun Yat-sen University · CNRhizen Pharmaceuticals (Switzerland) · CHThe Ohio State University Wexner Medical Center · US

Funding

Oncogenic Function of Ca2+ Channel Orai1 in Esophageal CarcinogenesisR01CA185055 · NCI · OHIO STATE UNIVERSITY · PI CHEN, TONG, PAN, ZUI · 2015 to 2019
$1.6M
NCI NIH HHS R01 CA185055
6 · The paper itself

Abstract

Esophageal cancer (EC) is the 6th leading cause of cancer mortality worldwide with poor prognosis, hence more effective chemotherapeutic drugs for this deadly disease are urgently needed. We previously reported that high expression of Orai1, a store-operated Ca

Indexed as

AnimalsAntineoplastic AgentsApoptosisCalciumCalcium Channel BlockersCalcium ChannelsCalcium SignalingCarcinoma, Squamous CellCell CycleCell MovementCell ProliferationEsophageal NeoplasmsHumansMaleMiceMice, NudeAntineoplastic AgentsCalciumCalcium Channel BlockersCalcium ChannelsNF-kappa BORAI1 ProteinORAI1 protein, humanOrganic ChemicalsRP4010Cell proliferationEsophageal cancerIntracellular Ca(2+) oscillationsSOCE

Identifiers

PMID29908962
PMCPMC6070391
OpenAlexW2807822532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.